Resources

Selected
  • Systematic reviews (SYSVAC)
Type of publications
Regions
Diseases
Vaccine topics
Target population
Publication date

3152 results found

2022 ∙ Flacco, M. E. Acuti Martellucci, C. Baccolini, V. De Vito, C. Renzi, E. Villari, P. Manzoli, L.

Risk of reinfection and disease after SARS-CoV-2 primary infection: meta-analysis

  • Adults
  • Older adults
  • Adolescents
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Chu, D. K. Abrams, E. M. Golden, D. B. K. Blumenthal, K. G. Wolfson, A. R. Stone, C. A., Jr. Krantz, M. S. Shaker, M. Greenhawt, M.

Risk of Second Allergic Reaction to SARS-CoV-2 Vaccines: A Systematic Review and Meta-analysis

  • Adults
  • Older adults
  • COVID-19
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Kechagias, K. S. Kalliala, I. Bowden, S. J. Athanasiou, A. Paraskevaidi, M. Paraskevaidis, E. Dillner, J. Nieminen, P. Strander, B. Sasieni, P. Veroniki, A. A. Kyrgiou, M.

Role of human papillomavirus (HPV) vaccination on HPV infection and recurrence of HPV related disease after local surgical treatment: systematic review and meta-analysis

  • All age groups
  • Human papillomavirus (HPV)
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Low
2022 ∙ Zhang, X. Xu, X. F. Jin, J.

Rotavirus vaccination and the risk of type 1 diabetes and celiac disease: A systematic review and meta-analysis

  • Newborn
  • Children
  • Adolescents
  • Rotavirus
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ SeyedAlinaghi, S. Karimi, A. Pashaei, Z. Afzalian, A. Mirzapour, P. Ghorbanzadeh, K. Ghasemzadeh, A. Dashti, M. Nazarian, N. Vahedi, F. Tantuoyir, M. M. Shamsabadi, A. Dadras, O. Mehraeen, E.

Safety and Adverse Events Related to COVID-19 mRNA Vaccines; a Systematic Review

  • Adolescents
  • Adults
  • Older adults
  • COVID-19
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Dadras, O. Mehraeen, E. Karimi, A. Tantuoyir, M. M. Afzalian, A. Nazarian, N. Mojdeganlou, H. Mirzapour, P. Shamsabadi, A. Dashti, M. Ghasemzadeh, A. Vahedi, F. Shobeiri, P. Pashaei, Z. SeyedAlinaghi, S.

Safety and Adverse Events Related to Inactivated COVID-19 Vaccines and Novavax;a Systematic Review

  • All age groups
  • COVID-19
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Mehta, N. Shah, S. Paudel, K. Chamlagain, R. Chhetri, S.

Safety and efficacy of coronavirus disease-19 vaccines in chronic kidney disease patients under maintenance hemodialysis: A systematic review

  • Older adults
  • COVID-19
  • Safety
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Tian, F. Yang, R.

Safety and Efficacy of COVID-19 Vaccines in Children and Adolescents: a Systematic Review of Randomized Controlled Trials

  • Newborn
  • Children
  • COVID-19
  • Safety
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Lopez-Olivo, M. A. Valerio, V. Karpes Matusevich, A. R. Brizio, M. Kwok, M. Geng, Y. Suarez-Almazor, M. E. Colmegna, I.

Safety and Efficacy of Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitors. Systematic Review with Meta-Analysis

  • All age groups
  • Influenza
  • Safety
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Low
2022 ∙ Xu, W. Tang, J. Chen, C. Wang, C. Wen, W. Cheng, Y. Zhou, M. Wu, Q. Zhang, X. Feng, Z. Wang, M.

Safety and efficacy of the COVID-19 vaccine in children and/or adolescents:A meta-analysis

  • Children
  • Adolescents
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
Loading...